WO2007009201A3 - Process to obtain synthetic and semi-synthetic lignan derivatives, their antiparasitic activities and corresponding pharmaceutical formulations, including the therapeutic method using said lignan for the treatment of parasitosis - Google Patents
Process to obtain synthetic and semi-synthetic lignan derivatives, their antiparasitic activities and corresponding pharmaceutical formulations, including the therapeutic method using said lignan for the treatment of parasitosis Download PDFInfo
- Publication number
- WO2007009201A3 WO2007009201A3 PCT/BR2006/000144 BR2006000144W WO2007009201A3 WO 2007009201 A3 WO2007009201 A3 WO 2007009201A3 BR 2006000144 W BR2006000144 W BR 2006000144W WO 2007009201 A3 WO2007009201 A3 WO 2007009201A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- synthetic
- lignan
- semi
- lignans
- therapeutic method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention refers to a process to obtain synthetic and semi-synthetic derivatives of lignans, especially dibenzylbutyrolactonic, tetrahydrofuranic, aryltetralynic, furofuranic and dibenzocyclooctanic lignans obtained by means of partial synthesis and/or full synthesis or also by isolation from plant extracts. It refers to a process to obtain synthetic and semi-synthetic derivatives of (-)-cubebin, such as: (-)-O-acetylcubebin; (-)-O-methylcubebin; (-)-O-N,N-(dimethylamino-ethyl)-cubebin; (-)-hinokinin; (-)-6,6’-dinitroinokinine; (-)-O-benzylcubebin; (-)-6,6'-diaminoinokinin, (-)-6,6’-dinitroinokinin, as well as to obtain dibenzocyclooctanic lignans from dibenzylbutyrolactoinic lignans by means of structural modifications in the positions 7, 7’, 8, 8’, 9’ and in the aromatic rings (introduction and/or substitution of functional groups such as: -OH, -CO2H, -CO2CH3, -NO2, -NH2, -OCH3, -OAc, -SO2CH3, -SO2NH2, prenyl and halogens). The invention also refers to a therapeutic method, since the substances described are used in the manufacture of medicine that presents antiparasitic activity.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06761026A EP1907380A4 (en) | 2005-07-15 | 2006-07-14 | Process to obtain synthetic and semi-synthetic lignan derivatives, their antiparasitic activities and corresponding pharmaceutical formulations, including the therapeutic method using said lignan for the treatment of parasitosis |
US11/995,789 US20080194678A1 (en) | 2005-07-15 | 2006-07-14 | Process To Obtain Synthetic And Semi-Synthetic Lignan Derivatives, Their Antiparasitic Activities And Corresponding Pharmaceutical Formulations, Including The Therapeutic Method Using Said Lignan For The Treatment Of Parasitosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0503951-7A BRPI0503951A (en) | 2005-07-15 | 2005-07-15 | process of obtaining synthetic and semi-synthetic derivatives of lignans, their antiparasitic activities and their pharmaceutical formulations, encompassing the therapeutic method using such lignans in the treatment of parasitic diseases. |
BRPI0503951-7 | 2005-07-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007009201A2 WO2007009201A2 (en) | 2007-01-25 |
WO2007009201A3 true WO2007009201A3 (en) | 2007-07-26 |
Family
ID=37669153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2006/000144 WO2007009201A2 (en) | 2005-07-15 | 2006-07-14 | Process to obtain synthetic and semi-synthetic lignan derivatives, their antiparasitic activities and corresponding pharmaceutical formulations, including the therapeutic method using said lignan for the treatment of parasitosis |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080194678A1 (en) |
EP (1) | EP1907380A4 (en) |
BR (1) | BRPI0503951A (en) |
WO (1) | WO2007009201A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8829049B2 (en) | 2009-12-21 | 2014-09-09 | Acef S.A. | Medicinal composition intended for the treatment of erectile dysfunction in mammals and use of the composition |
CN102451178A (en) * | 2010-10-29 | 2012-05-16 | 中国科学院上海药物研究所 | Application of dihydrofuran-2-ketone compounds in preparing medicament for resisting diabetes mellitus and glucose and lipid metabolism |
KR101918143B1 (en) | 2012-04-10 | 2018-11-15 | (주)아모레퍼시픽 | Method for preparing furofuran lignan compound |
CN112979625A (en) * | 2021-02-03 | 2021-06-18 | 广西馨海药业科技有限公司 | Synthesis method and application of piperlongumine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003080600A1 (en) * | 2002-03-25 | 2003-10-02 | Fundação De Amparo À Pesquisa Do Estado de São Paulo | Process to obtain dibenzylbutyrolactonic lignans; process to obtain synthetic derivatives from lignanes bearing anti-chagas chemoprophylactic and therapeutical activities |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002048097A1 (en) * | 2000-12-12 | 2002-06-20 | Corvas International, Inc. | Compounds, compositions and methods for treatment of parasitic infections |
-
2005
- 2005-07-15 BR BRPI0503951-7A patent/BRPI0503951A/en not_active IP Right Cessation
-
2006
- 2006-07-14 EP EP06761026A patent/EP1907380A4/en not_active Withdrawn
- 2006-07-14 WO PCT/BR2006/000144 patent/WO2007009201A2/en active Application Filing
- 2006-07-14 US US11/995,789 patent/US20080194678A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003080600A1 (en) * | 2002-03-25 | 2003-10-02 | Fundação De Amparo À Pesquisa Do Estado de São Paulo | Process to obtain dibenzylbutyrolactonic lignans; process to obtain synthetic derivatives from lignanes bearing anti-chagas chemoprophylactic and therapeutical activities |
Also Published As
Publication number | Publication date |
---|---|
WO2007009201A2 (en) | 2007-01-25 |
EP1907380A2 (en) | 2008-04-09 |
EP1907380A4 (en) | 2010-08-04 |
BRPI0503951A (en) | 2007-03-06 |
US20080194678A1 (en) | 2008-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Larit et al. | Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants | |
KR102078204B1 (en) | Compositions and methods for joint health | |
WO2007068894A3 (en) | Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease | |
WO2007020382A3 (en) | Plant-based medicament for the treatment of liver disease | |
Oh et al. | Calycosin and 8-O-methylretusin isolated from Maackia amurensis as potent and selective reversible inhibitors of human monoamine oxidase-B | |
RS20080167A (en) | Novel improved compositions for cancer therapy | |
CL2007002099A1 (en) | COMPOUNDS DERIVED FROM 3H-ESPIRO (1-BENZOFURAN-2,4'-PIPERIDINA); PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF RESPIRATORY DISEASES, SUCH AS COPD AND ASTHMA. | |
WO2007071963A3 (en) | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | |
UA104988C2 (en) | Novel pyrone-indole derivatives and process for their preparation | |
WO2007044950A3 (en) | Crystalline forms of docetaxel and processes for their preparation | |
MX344787B (en) | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders. | |
BRPI0508914A (en) | tissue detoxification and health supplements and processes for obtaining and using them | |
WO2011023367A3 (en) | Bisphosphonate-prodrugs | |
WO2005074989A3 (en) | Combination of a dna topoisomerase inhibitor and an iap inhibitor | |
WO2007009201A3 (en) | Process to obtain synthetic and semi-synthetic lignan derivatives, their antiparasitic activities and corresponding pharmaceutical formulations, including the therapeutic method using said lignan for the treatment of parasitosis | |
MX2010005704A (en) | Chromane derivatives as trpv3 modulators. | |
HK1104280A1 (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
Mir et al. | Evolution of natural product scaffolds as potential proteasome inhibitors in developing cancer therapeutics | |
NO20090067L (en) | Pharmaceutical combinations for the treatment of respiratory diseases | |
WO2007026254A3 (en) | Benzodiazepine derivatives , their preparation and the therapeutic use thereof | |
UA104861C2 (en) | Chromane derivatives as trpv3 modulators | |
NO20073046L (en) | Selected benzofuran derivatives | |
Chung et al. | Histone deacetylase inhibitors from the rhizomes of Zingiber zerumbet | |
WO2006134609A3 (en) | Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof | |
WO2016175589A3 (en) | Pharmaceutical composition for preventing or treating respiratory diseases, containing extract of mixed herbal medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006761026 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2006761026 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11995789 Country of ref document: US |